An Early-Phase Clinical Study to Evaluate the Tolerability, Safety, and Efficacy of VGN-Ex05e in Patients With Autism Spectrum Disorder (ASD) Associated With Severe, Treatment-Resistant Self-Injurious and Aggressive Behaviors
Latest Information Update: 17 Mar 2026
At a glance
- Drugs VGN Ex05e (Primary)
- Indications Autism spectrum disorder
- Focus Adverse reactions
Most Recent Events
- 17 Mar 2026 New trial record